Amneal receives FDA nod for leuprolide acetate injection
Leuprolide acetate injection is indicated in the palliative treatment of advanced prostatic cancer.
The Food and Drug Administration has cleared Amneal’s leuprolide acetate for injection, which is indicated in the palliative treatment of advanced prostatic cancer.
“We are making tremendous progress expanding our injectables business. This latest new product is another key therapeutic for the institutional market and another complex, high value launch by the team, ” said Harsher Singh, senior vice president for Amneal Biosciences.
[Read more: Amneal debuts 2 generics]
The product had a market value of $81 million for the 12 months ending September 2022, according to IQVIA.